in the mitigation of renal injury due to diabetes has been proposed. Kim et al. highlight recent advances about adiponectin and kidney diseases, describing adiponectin signaling pathways in healthy and disease conditions. In particular, the review discusses the possible strategies for upregulating adiponectin and adiponectin receptors and the possible use of the receptor agonist AdipoRon in the amelioration of overt diabetic kidney disease [13] . Furthermore, this Special Issue contains two research articles regarding adiponectin involvement in human follicular dermal papilla cells and the interaction of adiponectin with nerve growth factor β (NGFβ) and secreted protein acidic and rich in cysteine (SPARC). Park et al. report that kojyl cinnamate ester derivatives and Seletinoid G promote adiponectin secretion by human follicular dermal papilla cells. In addition, cell medium containing secreted adiponectin induces the expression of hair growth-related factors, thus suggesting an involvement of the hormone in the promotion of hair growth in humans [14] . Finally, Okura et al. investigate the interaction between adiponectin and NGFβ and SPARC. Surface plasmon resonance analysis demonstrated a physical interaction between adiponectin and NGFβ, and this interaction was confirmed in neuronal cultured PC12 cells [15] .
Collectively, the papers reported in this Special Issue reinforce the idea that adiponectin plays an important role at the systemic level and that hypoadiponectinemia is associated with many diseases. The exogenous administration of adiponectin has often beneficial effects in diseased tissues, suggesting that the planning of new drugs able to activate adiponectin signaling could be a new tool for the amelioration of several pathologies.
